Asset profile
epinephrine · Aquestive (AQST)
- Indication
- Type I allergic reactions, including anaphylaxis
- Also known as
- Anaphylm, Anaphylm Sublingual Film, AQST-109, epinephrine sublingual film
Company
AQSTAquestive
AQSTAquestiveAquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS),…
On the calendar
~
Quarter only
~ Quarter only
AQSTAquestive16
Mar 2027
Mar 16, 2027
in 136 days
AQSTAquestiveAquestive Anaphylm NDA resubmission accepted with PDUFA of March 16, 2027
Rescheduled — was Jan 31, 2026
Timeline
Newest first.
Oct 15, 2026
11:21 AM
AQSTAquestiveSep 17, 2026
11:02 AM
AQSTAquestiveAug 10, 2026
11:05 AM
AQSTAquestiveMar 30, 2026
11:44 AM
AQSTAquestiveRegistered trials
| Registry ID | Phase | Status | Primary completion | Enrollment | Sites |
|---|---|---|---|---|---|
| NCT02473263 | Phase 3 | Completed | Feb 9, 2019 | 398 | 0 of 1 sites in the United States |